Research Paper Volume 16, Issue 4 pp 3531—3553

Figure 8. Mutation analysis and sensitivity difference of antitumor drugs of BRCA. (A, B) The landscape map of the top 15 genes with the highest mutation frequency, among which PIK3CA, TP53, and TTN genes are more prone to mutation. (C) Variance analysis revealed that high-risk groups have a higher tumor mutation burden. (D) K–M survival curves between the high-TMB and low-TMB sets. (E) K-M survival curves between H-H/H-L/L-H/L-L sets. (F–I) Boxplot showed the differential IC50 of our previously established high-risk and low-risk groups in the TCGA cohort. The high-risk group was more sensitive to antitumor drugs, including BI.D1870, CMK, PF.4708671, and PHA.665752. (J) Variance analysis of ACTC1 between tumor and normal groups. (K) Survival analysis of ACTC1 in high and low-risk groups. (L) Association of ACTC1 and immune checkpoints. (M) After ACTC1 siRNA transfection into MDA-MB-231 and MCF-7 cell lines, the ACTC1 expression level was significantly reduced.